Finance

Beta
Lists
540222:BOM
Laurus Labs Ltd
₹1,447.00
+1.39%
(+19.80) 1D
Jun 5, 3:46:45 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 540222...
Open
₹1,442.10
High
₹1,449.90
Low
₹1,428.95
Mkt. cap
780.05B
Avg. vol.
172.65K
Volume
141.64K
Dividend
0.14%
Quarterly dividend
₹0.50
Ex-dividend date
May 8, 2026
P/E ratio
88.07
52-wk high
₹1,449.90
52-wk low
₹623.20
EPS
₹16.43
Shares outstanding
106.44M
No. of employees
6K
Open
₹1,442.10
High
₹1,449.90
Low
₹1,428.95
Mkt. cap
780.05B
Avg. vol.
172.65K
Volume
141.64K
Dividend
0.14%
Quarterly dividend
₹0.50
Ex-dividend date
May 8, 2026
P/E ratio
88.07
52-wk high
₹1,449.90
52-wk low
₹623.20
EPS
₹16.43
Shares outstanding
106.44M
No. of employees
6K
News stories
From sources across the web
Profile
Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers. The R&D centres are based in Hyderabad, Visakhapatnam and United States. Wikipedia
About Laurus Labs Ltd
CEOSatyanarayana Chava
Employees6.17K
Founded2005
Headquarters-
SectorPharmaceutical industry
Websitelauruslabs.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
15.70B
16.53B
17.78B
18.12B
Cost of goods sold
6.37B
6.63B
6.95B
7.00B
Cost of revenue
6.37B
6.63B
6.95B
7.00B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.15B
2.16B
2.29B
2.36B
Operating expense
6.67B
7.07B
7.24B
7.21B
Total operating expenses
13.04B
13.71B
14.19B
14.22B
Operating income
2.65B
2.83B
3.60B
3.90B
Other non operating income
104.30M
269.60M
57.60M
118.00M
EBT including unusual items
2.25B
2.70B
3.25B
3.62B
EBT excluding unusual items
2.25B
2.70B
3.25B
3.62B
Income tax expense
631.40M
759.80M
734.50M
794.60M
Effective tax rate
28.08%
28.09%
22.58%
21.98%
Other operating expenses
3.35B
3.71B
3.74B
3.64B
Net income
1.63B
1.95B
2.52B
2.79B
Net profit margin
10.39%
11.79%
14.15%
15.41%
Earnings per share
3.02
3.61
4.65
5.17
Interest and investment income
-
-
-
-
Interest expense
-515.00M
-400.00M
-387.90M
-404.40M
Net interest expenses
-515.00M
-400.00M
-387.90M
-404.40M
Depreciation and amortization charges
1.17B
1.20B
1.21B
1.22B
EBITDA
3.68B
4.01B
4.62B
5.10B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer